Single-domain antibodies, often called nanobodies, are the smallest naturally derived antigen-binding fragments known, weighing in at roughly 12 to 15 kilodaltons compared to about 150 for a conventional antibody. Their compact structure gives them surprising toughness, but recent innovations in engineering, computational design, and chemical modification have pushed that stability even further, opening doors that conventional antibodies simply cannot fit through. The science of making these tiny proteins more resilient, more versatile, and easier to produce is moving fast, with consequences for drug development, diagnostics, and basic research tools alike.
What Makes These Antibodies So Small and Sturdy
Conventional antibodies are Y-shaped molecules built from two heavy chains and two light chains. The antigen-binding site sits at the tip of each arm, formed by variable regions from both chains working together. Single-domain antibodies skip this arrangement entirely. Found naturally in camels, llamas, alpacas, and sharks, heavy-chain-only antibodies use just a single variable domain to grab their target. That domain, isolated and produced on its own, is the nanobody.
Because a nanobody is a single protein domain with no partner chain to worry about, it folds independently and tends to refold well after being heated or chemically stressed. The core is stabilized by a conserved disulfide bond that pins the two main structural sheets together. Many nanobodies also have elongated loops that can reach into grooves and pockets on target proteins, accessing surfaces that bulkier antibodies cannot. Their small size, thermal tolerance, and ability to be produced in simple microbial systems are not separate advantages but direct consequences of this stripped-down architecture.
Disulfide Bond Engineering
The naturally occurring disulfide bond in a nanobody’s core is essential for holding the domain together. But researchers have found that adding extra disulfide bonds in carefully chosen locations can significantly improve stability under heat, organic solvents, and extreme pH conditions. Using an anticarbaryl nanobody as a test case, one group showed that introducing disulfide bonds between two internal sheets, or anchoring a flexible binding loop to a nearby sheet, boosted resilience across all three stress types.1PubMed. An Effective Way to Introduce Disulfide Bonds into Nanobodies: Using an Anticarbaryl Nanobody Structure as a Model A separate study looking specifically at naturally occurring extra disulfide bonds in nanobodies found that this particular type of additional bond consistently improved both conformational and thermal stability without interfering with antigen binding.2PubMed. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains
The picture gets more nuanced with shark-derived single-domain antibodies, known as VNARs. In one shark-derived nanobody called 2E6, removing a noncanonical disulfide bond between the first and third binding loops actually improved its ability to refold after heating and prevented thermal aggregation. That same modification reduced the protein’s overall structural rigidity and binding strength, but enhanced its ability to hold onto its target at elevated temperatures.3ACS Biomaterials Science & Engineering. Impact of Noncanonical Disulfide Bond on Thermal Resistance and Binding Affinity of Shark-Derived Single-Domain Antibodies The lesson here is that disulfide bonds are not universally beneficial. Where you put them, and in which structural context, determines whether you get a tougher protein or simply a stiffer one that breaks instead of bending.
Computational Approaches to Aggregation and Shelf Life
One of the biggest practical problems with any protein drug is aggregation, the tendency for molecules to clump together over time. Aggregates reduce potency and can trigger immune reactions. For nanobody-based therapeutics heading toward the clinic, this is a real barrier. Recent computational work has started to address this by building mechanistic models of how aggregation and degradation happen, then using those models to identify the specific amino acid positions responsible.
In one case, researchers modeled an anticancer nanobody-Fc fusion called VFA01 and pinpointed five hotspot residues driving instability. They then designed a triple-mutant variant, M11, in which three of those residues were swapped. The result was striking: visible particles in solution were eliminated, the rate of size increase over time improved by about six-fold, and high-molecular-weight impurities dropped by roughly three-fold. Both antigen binding and production yield also improved by about 50 percent.4Advanced Science. Enhancing the Protein Stability of an Anticancer VHH-Fc Heavy Chain Antibody through Computational Modeling and Variant Design This kind of rational, computation-first approach to stability is becoming more practical as molecular simulation tools improve, and it avoids the trial-and-error of screening thousands of random mutations.
Surviving the Gut and Other Hostile Environments
One of the more ambitious applications for nanobodies is oral delivery, using them to neutralize toxins or pathogens directly in the gastrointestinal tract. The challenge is obvious: the GI environment is a gauntlet of acid, bile salts, and proteases designed to destroy proteins. The good news is that the compact, tightly folded core of a nanobody resists these conditions far better than the floppy tails and tags that researchers often attach to it. In studies exposing nanobodies to intestinal fluid, unstructured additions like epitope tags and flexible linkers were rapidly chewed up by digestive enzymes, while the functional nanobody core remained intact.5PLOS ONE. Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies
That said, individual nanobodies varied enormously in how well they survived. Among four tested nanobodies designed to neutralize Shiga toxin, one lost all detectable activity within 20 minutes of exposure to intestinal fluid, while the most resilient one remained active after three hours and was still detectable after overnight incubation.5PLOS ONE. Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies This range matters because it means protease resistance is not a given for nanobodies as a class. It depends heavily on the specific sequence and structure, which in turn means it can be selected for or engineered in.
Beyond gut survival, some nanobodies show broad resilience to manufacturing-relevant stresses. One nanobody developed to inhibit neutrophil elastase, called NbE201, proved highly stable against oxidation, deamidation, and both chemical and thermal denaturation, properties that suggest it would tolerate standard drug manufacturing processes without losing activity.6PubMed Central. Enzymatic, structural, and biophysical characterization of a single-domain antibody (VHH) selectively and tightly inhibiting neutrophil elastase and exhibiting favorable developability properties
Flexible Production Platforms
Because nanobodies are single domains with no light chain to pair and no complex glycosylation required for function, they can be produced in a wider range of host organisms than conventional antibodies. Both bacterial and yeast systems work, each with trade-offs. Bacteria like E. coli are cheap and fast but sometimes produce nanobodies that misfold or end up in insoluble aggregates. Yeast systems like Pichia pastoris secrete the nanobody into the culture medium, simplifying purification, and tend to produce properly folded protein.7PubMed Central. Recombinant expression of nanobodies and nanobody-derived immunoreagents
The yield difference can be substantial. In a head-to-head comparison of an anti-EGFR nanobody, Pichia expression delivered 6 to nearly 14 times more protein than E. coli, and both versions retained the ability to internalize into tumor cells.8PubMed. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties More recently, Pichia has been validated as a host for producing isotope-labeled nanobodies for structural studies, generating protein with native-like folding and binding activity comparable to material from mammalian cell culture, but at a fraction of the cost and complexity.9PubMed Central. Production of isotope-labeled nanobody KN035 in Pichia pastoris yields native-like conformation and PD-L1 binding activity comparable to KN035 expressed in mammalian cells The practical upshot is that researchers can iterate quickly on nanobody designs without needing expensive mammalian expression systems, which accelerates both discovery and early-stage development.
Humanization and Solubility
Nanobodies come from camels or sharks, and the human immune system might recognize them as foreign. Humanization, the process of swapping in human-like amino acid residues while keeping the binding activity intact, is a standard step before clinical use. But it is tricky with nanobodies because many of the residues that distinguish a camelid nanobody from a human antibody domain are the same residues responsible for the nanobody’s solubility and stability. Swap too many and the protein falls apart or aggregates.
Systematic humanization studies have tackled this by identifying which positions in the structural framework can safely accept human residues and which are load-bearing for nanobody function. In one study, key positions in the structural support regions were exchanged with residues from the closest human germline sequences, and the resulting variants were checked for binding affinity, yield, and purity, with crystal structures solved to understand any binding differences.10PubMed Central. On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality This kind of position-by-position mapping is building a playbook that other nanobody developers can use, reducing the guesswork involved.
A parallel innovation is the construction of fully synthetic nanobody libraries, where the framework is designed from scratch to incorporate the amino acid substitutions that keep nanobodies soluble without needing a camelid-derived starting sequence at all. One such library introduced specific substitutions at four positions in the structural framework that are critical for solubility, effectively building in the biophysical advantages of nanobodies while starting from a human-compatible scaffold.11Korean Journal of Physiology & Pharmacology. Construction and validation of a synthetic phage-displayed nanobody library These synthetic libraries bypass the need for immunizing an animal entirely, which is both faster and more scalable.
Bispecific and Multivalent Formats
A single nanobody binds a single target. But because nanobodies are small, you can link two or more of them together into bispecific or multivalent constructs without creating an unwieldy molecule. A conventional bispecific antibody is a major engineering project; linking two nanobodies with a short peptide is comparatively straightforward.
These linked constructs can hit two different targets simultaneously, which is useful for diseases driven by multiple signaling pathways. In one example, a bispecific nanobody construct was designed to bind both TNF-alpha and IL-23, two inflammatory molecules involved in autoimmune diseases. When tested against either target alone, the construct bound with affinities around 10 to 13 nanomolar. But when both targets were present together, the effective affinity jumped to about 1 nanomolar, a clear avidity effect where each binding arm helps anchor the other.12PubMed Central. Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations This roughly ten-fold improvement in apparent binding strength comes essentially for free from the format itself.
Reaching Difficult Tissues
The small size of nanobodies is not just a manufacturing convenience. It has direct therapeutic implications for reaching tissues that conventional antibodies cannot easily penetrate. The blood-brain barrier is the classic example. Full-size antibodies are almost completely excluded from the brain, which is a major obstacle for treating neurological diseases.
Nanobodies targeting the transferrin receptor, a protein expressed on blood-brain barrier cells, have been engineered to cross into the brain by hitching a ride on the receptor’s natural transport machinery. In one study, researchers fused nanobodies to a neuropeptide that only works inside the brain. When injected intravenously, one of the nanobody fusions caused a measurable drop in body temperature in mice, a clear sign that the neuropeptide had reached its target in the central nervous system.13PubMed Central. Identification and in vivo characterization of a brain-penetrating nanobody Careful design was required: the nanobody fusions were engineered with acidic peptide tags to keep their overall charge low, avoiding nonspecific uptake through charge-based mechanisms that would muddy the results.
The lungs represent another attractive delivery route. For respiratory infections, delivering nanobodies directly to the airways via inhalation would put the drug right where it is needed. Nanobodies are well suited for this because their stability allows them to survive the shearing forces and temperature changes involved in nebulization, a process that can denature less robust proteins. Their resistance to harsh manufacturing conditions also means they can be formulated into dry powders or aerosols without losing activity.14PubMed Central. Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
Tools for Structural Biology
Outside of therapeutics and diagnostics, nanobodies have become indispensable in basic research. Their ability to lock proteins into specific shapes has made them a favorite tool for structural biologists trying to solve the three-dimensional structures of flexible or unstable proteins.
Nanobodies can be selected to bind only one conformation of a protein, effectively freezing it in that state for imaging. This has been used extensively with X-ray crystallography, where a floppy protein that refuses to crystallize on its own can be coaxed into forming crystals when a nanobody holds it still. The same principle extends to cryo-electron microscopy, and nanobodies engineered as conformational biosensors can even be expressed inside living cells to track where and when a protein switches between states.15PubMed. Nanobodies to study protein conformational states
A particularly powerful recent development is the creation of a “universal” nanobody for structural work. Researchers demonstrated that the same nanobody, recognizing a short grafted intracellular loop, could be used to solve cryo-electron microscopy structures of multiple different G-protein-coupled receptors in their inactive state, achieving resolutions comparable to or better than X-ray crystallography.16PubMed Central. Structure determination of inactive-state GPCRs with a universal nanobody GPCRs are among the most important drug targets in medicine, and getting high-resolution structures of their inactive conformations has historically been difficult. A single reusable nanobody tool that works across the family is a meaningful shortcut.
Biosensors That Work Outside the Freezer
For diagnostic and environmental sensing applications, the stability of nanobodies is not a luxury. It is the whole point. Conventional antibody-based biosensors typically need cold storage and careful handling, limiting their use in field settings or resource-limited environments. Nanobodies, with their superior thermal tolerance and pH resistance, are natural candidates for rugged, shelf-stable sensors.17PubMed Central. Immobilization of Nanobodies with Vapor-Deposited Polymer Encapsulation for Robust Biosensors
Vapor-deposited polymer coatings have been used to encapsulate nanobodies immobilized on sensor surfaces, creating a thin protective barrier that preserves activity and specificity even after storage at room temperature and complete desiccation. The resulting sensors retained their function after conditions that would destroy most antibody-based devices. For applications like point-of-care diagnostics in tropical climates or field-deployed environmental monitors, this kind of ruggedness transforms what is technically possible.
Site-Specific Chemical Conjugation
Attaching a nanobody to a drug, a fluorescent label, or a nanoparticle without disrupting its binding ability is a significant chemical challenge. Random conjugation methods, where a reactive chemical modifies whatever amino acid it happens to encounter on the surface, often hit residues in or near the binding site and kill the nanobody’s function. Site-specific conjugation solves this by placing the chemical modification at a defined, safe location on the protein.
One recent approach uses an enzymatic method to transfer a short peptide bearing a chemical handle onto a single specific amino acid near the C-terminus of the nanobody, far from the binding site. The handle then participates in a selective chemical reaction that links the nanobody to whatever cargo is needed, whether a small molecule drug, another nanobody, or a full-size antibody. The chemistry works at low protein concentrations and is highly selective, making it practical for real applications.18PubMed. Chemoenzymatic Site-Specific Lysine Modification of Nanobodies and Subsequent Bioconjugation via Potassium Acyltrifluoroborate (KAT) Ligations
For super-resolution microscopy, where the size of the labeling probe directly affects image resolution, nanobodies conjugated to short DNA strands have been validated as functional probes. Site-specific attachment of the DNA strand preserved target binding, as confirmed by both binding assays and imaging, enabling a technique where fluorescent signals are generated only at the precise location of the target molecule.19PubMed Central. Site-specific nanobody-oligonucleotide conjugation for super-resolution imaging Using a nanobody instead of a full antibody as the targeting probe means the label sits closer to the actual target, which in super-resolution microscopy is the difference between a useful image and a blurry one.
Nanobodies Working Inside Living Cells
Most antibody-based tools work outside cells or on cell surfaces, because conventional antibodies need disulfide bonds that only form properly in the oxidizing environment outside the cell. The interior of a cell is chemically reducing, which means those bonds do not form and the antibody misfolds. Nanobodies, with their minimal reliance on a single core disulfide bond and their ability to fold independently, are far more tolerant of intracellular expression. This has made them the dominant platform for intrabodies, antibody fragments expressed and functional inside living cells.20PubMed Central. Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell
Intrabodies derived from nanobodies can be used to visualize where a target protein is located in real time, track its movement, or block its function by binding and sequestering it. This turns nanobodies from therapeutic and diagnostic agents into basic research tools that operate at the level of individual cells. For studying proteins that are difficult to target with small-molecule drugs or that have no good chemical probes, a well-chosen nanobody intrabody can provide both the tool for studying the biology and the proof-of-concept that the target is druggable at all.